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Aim. To investigate the epidemiology and risk factors of Clostridium diﬃcile infections (CDI) in patients with inﬂammatory bowel
disease (IBD). Methods. This is a retrospective study of patients diagnosed with IBD. 1006 charts were screened and 654 patients
met the inclusion criteria. Patients were divided into 2 cohorts based on the presence of prior diagnosis of CDI. Statistical
analysis with Pearson’s chi-squared and two-sample t-test was performed. Results. The incidence of CDI among IBD
patients was 6.7%. There was equal prevalence of CDI among Crohn’s disease (CD) (n = 21, 49%) and ulcerative colitis
(UC) (n = 22, 51%). IBD patients acquired CDI at a mean age of 42.7 years, with 56% of infections acquired in the
community and only 28% associated with healthcare. Only 30% of IBD patients with CDI had prior antibiotic use, and
16% had prior steroid use. IBD patients were signiﬁcantly more likely to require biologic therapy (57% versus 37%, p < 0 01) and
have extraintestinal manifestations of IBD (43% versus 28%, p < 0 02). Conclusions. IBD patients are more susceptible to CDI at a
younger age and often lack traditional risk factors. IBD patients with at least one CDI were more likely to require biologic
therapy and had greater rates of extraintestinal manifestations.
1. Introduction
Clostridium diﬃcile is the major cause of infectious diarrhea
in hospitalized patients [1] and is the primary infectious
cause of pseudomembranous colitis [2]. Recent studies have
shown that infections with Clostridium diﬃcile (CDI) have
shown increased incidence, severity, and recurrence rates
over the past 10 years [3]. In addition, such infection has
recently surpassed that of methicillin-resistant Staphylococ-
cus aureus as the leading hospital-acquired infection in the
United States [4, 5]. These infections lead to longer hospital
stays, more frequent readmissions, and increased mortality
among hospitalized patients [4]. Healthcare costs related to
CDI are estimated to be around $1.8 billion annually in the
United States, can add over $11,000 to a patient’s hospital
stay, and increase the length of stay by an average of 3.3 days
[6]. There are several risk factors for CDI, with antibiotic use
being the most well-known. Others include advanced age,
increased severity of underlying illness, prior hospitalization,
feeding tube use, gastrointestinal surgery, and potentially
proton-pump inhibitors [7].
Patients with inﬂammatory bowel disease (IBD), which
includes Crohn’s disease (CD) and ulcerative colitis (UC),
have been shown to have increased CDI rates and dispropor-
tionately higher morbidity and mortality compared to CDI
patients without IBD [8, 9]. Classical risk factors may not be
found in many IBD patients, and clinical ﬁndings such as
pseudomembranes may not be present [3]. In contrast to
archetypal epidemiological studies, CDI is now being increas-
ingly recognized as a cause of diarrhea in the community,
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especially in younger individuals and in populations lacking
the traditional risk factors [10–12]. This study seeks to further
characterize the epidemiology and risk factors for C. diﬃcile
infections in IBD patients.
2. Methods
This was a retrospective study. The medical records of 1006
patients who carried the ICD 9 code for IBD (ICD-9: 555.x
and 556.x) at a single large academic medical center from
October 1, 2014, to September 30, 2015, were reviewed.
Approval was obtained from the Committee for the Protec-
tion of Human Subjects for the ﬁnalized study protocol.
Eligible patients were identiﬁed through a search of the elec-
tronic medical record, and data was deidentiﬁed and
randomized prior to analysis. Eligible patients had a previous
diagnosis of IBD based on ICD coding along with appro-
priate clinical symptoms and compatible endoscopic or
imaging ﬁndings. 352 patients were excluded due to insuf-
ﬁcient data to conﬁrm IBD diagnosis or inappropriate
coding. For the remaining 654 patients, extensive back-
ground epidemiologic and comorbid data were collected
for each subject and incorporated into the ﬁnal analysis.
The data extracted from the charts included the current
age of the patients, the age of IBD diagnosis, the type of
IBD, peak therapy between the time of diagnosis and the
current time of the study, extraintestinal manifestations,
hospitalization data, inﬂammatory markers, and antibiotic
and steroid use, among many others (Tables 1–3). For
subanalysis, patients were divided into those with prior
documented CDI and those without documented CDI.
Statistical analysis with Pearson’s chi-squared test and
two-sample t-test was performed.
3. Results
3.1. Epidemiology. A total of 654 IBD patients were studied.
43 patients (6.7%) had at least one conﬁrmed CDI. A review
of baseline characteristics revealed a mean patient age of
42.7 years at the time of the ﬁrst CDI, with 55.8% male pre-
dominance (Tables 1 and 3). This gender distribution is
similar to that of IBD patients without prior CDI (52.5%
male). Patients with prior CDI were more likely to have
been hospitalized with at least one IBD-related admission
compared to IBD patients without CDI (72% versus 42%,
p < 0 001). The mean number of IBD-related hospitaliza-
tions of patients with CDI was 2.9, and that of IBD
patients without CDI was 1.12 (p < 0 001). 43% of IBD
patients with past CDI eventually required surgery, while
only 33.5% of those without prior CDI ultimately required
a surgical procedure (but this was not statistically signiﬁcant
with p = 0 15).
3.2. CDI Characteristics. The mean age of diagnosis of CDI in
IBD patients was 42.7 years (Table 3). Interestingly, 56% of
these patients had community-acquired CDI (as per the most
recent IDSA guidelines [13]), with only 28% of CDI
being hospital-acquired and 16% being indeterminate. Of
those patients with CDI, only 30% used an antibiotic
within 1 month of diagnosis. Additionally, only 16% used
steroids within 1 month prior to CDI diagnosis. For the
initial treatment of CDI, 44% received oral metronidazole,
32.5% received oral vancomycin, and 11% received intrave-
nous solumedrol. Seven patients (16%) had more than one
CDI (occurring >8 weeks after completion of treatment
and resolution of symptoms), and two patients had multiple
recurrences. Of the patients with recurrent disease, all had
initial treatment with PO metronidazole. The average time
to disease clearance (deﬁned as resolution of symptoms
after completion of treatment or documented negative
PCR) was 20.1 days.
3.3. IBD Characteristics. IBD patients with at least one CDI
were signiﬁcantly more likely to require escalation to biologic
therapy when compared to IBD patients without prior CDI
(57% versus 38%, p < 0 01, Table 2). Only 14 patients were
actively on a biologic at the time of their ﬁrst CDI diagnosis.
Of a total of 256 patients on biologic agents, only 14 patients
(5.5% of all biologic users) developed CDI while on a bio-
logic. There were no signiﬁcant diﬀerences among the
types of biologic. Only 18% of patients with prior CDI
were able to control their IBD with salicylates alone, while
31% of those without prior CDI attained adequate control
with salicylates, but this was not statistically signiﬁcantly
diﬀerent (p = 0 08).
IBD patients with prior CDI had a higher rate of
extraintestinal manifestations of IBD than those without
prior CDI (43% versus 28%, p = 0 02). These included inﬂam-
matory arthritis, osteoporosis, osteomalacia, pyoderma gang-
renosum, psoriasis, and chronic pancreatitis. The lowest
mean albumin of those with prior CDI was 2.98, compared
to 3.45 in those without prior CDI (p < 0 001). Mean peak
ESR and CRP were also more elevated in those with
CDI, but this was not statistically signiﬁcant (p = 0 07
and p = 0 06, resp.).
With regard to the IBD subtype in patients with prior
CDI, 51% had UC and 49% had CD. This distribution was
similar to that of IBD patients without CDI (43% UC and
Table 1: IBD demographics.
IBD patients with
prior CDI (n = 43)
IBD patients without
prior CDI (n = 611)
Male, n (%) 24 (55.8) 321 (52.5)
Crohn’s disease, n (%) 21 (48.8) 344 (56.3)
Ileal 5 (23.8) 89 (25.6)
Colonic 5 (23.8) 81 (23.2)
Ileocolonic 10 (47.6) 150 (43.1)
Isolated upper
disease
1 (4.8) 24 (6.9)
Ulcerative colitis, n (%) 22 (51.2) 267 (43.6)
Pancolitis 10 (45.5) 119 (46.3)
Left-sided colitis 7 (31.8) 60 (23.3)
Proctosigmoiditis 2 (9) 50 (19.4)
Proctitis 3 (13.6) 28 (10.9)
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57% CD). These results show no statistically signiﬁcant
correlation between the IBD subtype and CDI. Overall,
8.3% of all UC patients and 6% of all CD patients studied
had at least one CDI. As expected, the anatomical distribu-
tion of IBD in those with CDI predominantly involved the
colon. Of those with CDI in UC, 45% had pancolitis, 31.8%
had left-sided colitis, 9% had proctosigmoiditis, and 13%
had proctitis. These results very closely mirror the distribu-
tion of UC in those without CDI. Similarly, in patients with
CDI in CD, 23% had either isolated ileal or colonic disease,
48% had ileocolonic disease, and only 4% had isolated upper
disease. This distribution is almost identical to the prevalence
of CD subtypes in patients without CDI.
4. Discussion
Our study analyzed a large (n = 654) cohort of IBD patients
for epidemiologic and comorbid conditions. Of these IBD
patients, 43 (6.7%) had proven CDI. This incidence is con-
cordant with that of other epidemiological studies of CDI
in IBD, with rates ranging from 3% to 6% [3, 14, 15]. This
rate has nearly doubled over the past decade and is far greater
than that in those patients without IBD (0.04% to 0.08%)
[14]. The majority of CDI in this study were diagnosed using
PCR for the C. diﬃcile toxin B gene in patients with clinical
symptoms of infection. Two patients were diagnosed with
CDI using an immunoassay for toxins A and B.
The mean age for patients with IBD who contracted CDI
was only 42.7 years in this study. This is in stark contrast to
the mean age of non-IBD patients most susceptible to CDI,
which ranges from 65 to 75 years of age depending on the
study [16–20]. Increased age is a well-recognized risk factor
for CDI; however, some studies have shown that IBD patients
appear to be more susceptible at a younger age [12, 15]. It is
tempting to attribute this skewed age distribution to
increased hospitalizations, antibiotic use, and/or immuno-
suppression in younger IBD patients, but these factors do
not account for the majority of CDI cases in this study.
Our data shows that those IBD patients with prior CDI
were signiﬁcantly more likely to have had at least one hospi-
talization for an IBD-related cause (72% versus 41%). Addi-
tionally, those IBD patients with prior CDI were
signiﬁcantly more likely to have multiple hospitalizations
(mean 2.9 versus 1.1). Despite the increased incidence and
number of hospitalizations in those with prior CDI, our data
shows that 56% of infections were community-acquired. This
is in contrast to the data from Europe, Canada, and the
United States suggesting a rate of 20–27% community-
acquired CDI in the general population [21–23].
In this study, we used the most recent Infectious Diseases
Society of America recommendations, which state that CDI
is community-acquired if the patient has not been discharged
from a healthcare facility in the previous 12 weeks and symp-
toms begin in the community or within 48 hours of admis-
sion to a hospital. Hospital-acquired CDI is deﬁned as a
symptom onset more than 48hrs after admission or less than
4 weeks after discharge, and CDI is considered indeterminate
if symptoms occur in the community between 4 and 12 weeks
after discharge [14]. In contrast to the 56% rate of
community-acquired CDI, only 28% of infections were
hospital-acquired and 16% indeterminate. This is directly a
counter to the traditional view of CDI as a predominantly
healthcare-associated infection. Our results are consistent
with those of other retrospective population studies of both
adults and children showing that IBD patients with CDI were
younger and more often had acquired infections as
Table 2: IBD characteristics.
IBD patients with prior
CDI (n = 43)
IBD patients without prior
CDI (n = 611)
Univariate analysis
p value
≥1 IBD-related hospitalization, n (%) 32 (72) 255 (41.7) p < 0 001
Number of IBD-related hospitalizations, mean± SD 2.9± 3.1 1.12± 2.27 p < 0 001
Surgery for IBD, n (%) 19 (43.2) 205 (33.5) p = 0 150
Biologic as peak IBD therapy, n (%) 25 (56.8) 231 (37.8) p = 0 008
Salicylate as peak IBD therapy, n (%) 8 (18) 189 (30.9) p = 0 088
Extraintestinal manifestations of IBD, n (%) 19 (43) 174 (28.4) p = 0 021
Lowest albumin, mean± SD 2.98± 0.83 3.45± 0.79 p < 0 001
Peak CRP, mean± SD 55.9± 64.8 37.8± 58.3 p = 0 065
Peak ESR, mean± SD 43.5± 31.5 35± 28.2 p = 0 071
CRP = C-reactive protein, ESR = erythrocyte sedimentation rate.
Table 3: CDI characteristics.
IBD patients with prior
CDI (n = 43)
Age at ﬁrst CDI (years), mean± SD 42.7± 19.9
CDI etiology, n (%)
Community-acquired 24 (56)
Hospital-acquired 12 (28)
Indeterminate 7 (16)
Antibiotic use prior to CDI, n (%) 13 (30)
Steroid use prior to CDI, n (%) 7 (16.3)
Biologic use at the time of CDI, n (%) 14 (32.5)
Time to CDI clearance (days), mean± SD 20.6± 14.27
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outpatients compared with patients without IBD [15, 24].
The majority of CDI were community-acquired; only 30%
had antibiotic use within one month of diagnosis. These
ﬁndings demonstrate the lack of traditional risk factors
for CDI in patients with IBD. This awareness is crucial
for accurate diagnosis. CDI may mimic or precipitate an
IBD ﬂare, but these two entities have distinctly divergent
treatment plans. Empiric treatment with glucocorticoids
in CDI without appropriate antibiotic coverage has been
associated with higher short-term mortality [25], so proper
diagnosis is essential.
In regard to immunosuppression, those IBD patients
with at least one CDI were signiﬁcantly more likely to require
escalation to biologic therapy when compared to IBD
patients without CDI (57% versus 38%). The overwhelming
majority of biologic agents observed in this study were the
TNF-alpha inhibitors inﬂiximab and adalimumab. Similarly,
only 18% of patients with prior CDI were able to control their
disease with salicylates alone, while 31% of those without
CDI attained adequate control with salicylates (but this was
not statistically signiﬁcant with p = 0 08). These ﬁndings
could represent an increased susceptibility to CDI in those
patients with more severe or aggressive IBD. In IBD, dys-
function of regulatory T cells or antigen-presenting cells
can lead to a loss of tolerance to ubiquitous microbial anti-
gens [26]. The concentrations of mucosal bacteria of the
colon have been shown to increase progressively with the
severity of disease, both in the inﬂamed and noninﬂamed
colon [27]. While the results of speciﬁc microbial dysbiosis
in IBD vary between studies, the most consistent observation
is reduced bacterial diversity [28]. It is known that reduced
microbial diversity in the gut is a common pathogenic
pathway for CDI; therefore, those patients with more
severe IBD may be more innately susceptible to CDI.
Perhaps, a more apparent cause of increased CDI in
this population would be the direct immunosuppressive
eﬀects of biologic agents themselves. However, studies have
shown conﬂicting data on the role of TNF-alpha inhibitors
such as inﬂiximab and adalimumab in increasing suscepti-
bility to CDI [28–30]. In our study, the majority of patients
who had CDI would eventually require a biologic; however,
only 14 patients were actively on a biologic at the time of
CDI diagnosis. In addition, there was no recurrence of
CDI after patients were started on a biologic. Overall, only
5.4% of the 256 patients on a biologic agent were diag-
nosed with CDI. Similarly, only 16% of patients were on
systemic corticosteroids or immunomodulators within one
month of CDI diagnosis. While immunosuppressive agents
certainly increase susceptibility to opportunistic infections,
they did not appear to be the principal risk factor for
CDI in this study.
Patients with at least one CDI were more likely to have
extraintestinal manifestations of IBD than those patients
without CDI (43% versus 28%). These included inﬂamma-
tory arthritis, osteoporosis, osteomalacia, pyoderma gangre-
nosum, psoriasis, and chronic pancreatitis. While both
arthritis and osteoporosis are very common conditions, the
majority of these patients developed these conditions at an
age younger than 60 years. IBD patients with at least one
CDI also had lower mean albumin than those without CDI
(2.98 versus 3.45).
There are some limitations to this study. This study was
retrospective. We were unable to evaluate the severity of
CDI due to the large proportion of community-acquired
and indeterminate infections. Data was provided by a large
number of outside providers with variability in data collected
or accessible around the time of diagnosis. Similarly, the CDI
cohort consists of only those patients who were admitted to
our hospital with CDI or were followed up by one of our out-
patient providers around the time of diagnosis. There are
likely patients in the IBD cohort who were diagnosed or
treated for CDI at outside facilities without our knowledge,
leading to underestimation of CDI incidence and an incom-
plete CDI cohort. Finally, the toxin B PCR cannot distinguish
between new infection and asymptomatic carriage, compli-
cating diagnosis in this population given the similarity of
symptoms between CDI and an IBD ﬂare.
This study demonstrates an equal prevalence of CDI in
UC and CD. It shows that IBD patients are more susceptible
to CDI at a younger age and often lack traditional risk factors
such as recent hospitalization or antibiotic use. Additionally,
IBD patients with at least one CDI were more likely to
require biologic therapy, had lower success with salicylates,
had lower mean albumin, and had greater rates of extraintes-
tinal manifestations.
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